[Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D000069446:Atazanavir Sulfate; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced* / Q000517:prevention & control; D009842:Oligopeptides / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D014280:Triglycerides; D000069446:Atazanavir Sulfate; D002784:Cholesterol